计算溶液所需的质量、体积或浓度。
活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
A408935-1ml |
1ml |
现货 ![]() |
|
英文别名 | 5-Pyrimidinecarboxamide, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)- |
---|---|
规格或纯度 | Moligand™, 10mM in DMSO |
英文名称 | Avanafil |
生化机理 | 阿伐那非是一种高选择性 PDE5 抑制剂,其 IC50 值为 5.2 nM,比其他 PDEs 的选择性高出 121 倍。 |
储存温度 | -80℃储存 |
运输条件 | 超低温冰袋运输 |
作用类型 | 抑制剂 |
作用机制 | 磷酸二酯酶 5A 抑制剂 |
产品介绍 |
Avanafil is a highly selective PDE5 inhibitor with IC50 of 5.2 nM, >121-fold selectivity over other PDEs. Information Avanafil is a highly selectivePDE5inhibitor withIC50of 5.2 nM, >121-fold selectivity over other PDEs. In vivo Avanafil (i.v.) potentiates penile tumescence with ED200% of 37.5 μg/kg in dogs. Furthermore, intraduodenal treatment of Avanafil potentiates pelvic nerve stimulation induced changes in intracavernous pressure and duration. The cavernous injection of avanafil (1 μM) in T2DM rats results in partial improvement in erectile responses. cell lines: Concentrations: Incubation Time: Powder Purity:≥99% |
IC50 | PDE5, IC50: 1 nM |
---|---|
ALogP | 2.165 |
hba_count | 6 |
HBD Count | 3 |
Rotatable Bond | 9 |
分子类型 | 小分子 |
---|---|
Canonical SMILES | COC1=C(Cl)C=C(CNC2=C(C=NC(=N2)N3CCCC3CO)C(=O)NCC4=NC=CC=N4)C=C1 |
分子量 | 483.95 |
Reaxy-Rn | 38205117 |
Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=38205117&ln= |
溶解性 | Solubility (25°C) In vitro DMSO: 74 mg/mL (200.31 mM); Water: Insoluble; Ethanol: Insoluble; |
---|---|
DMSO(mg / mL) Max Solubility | 97 |
DMSO(mM) Max Solubility | 200.43 |
Water(mg / mL) Max Solubility | <1 |
Reaxy-Rn | 38205117 |
---|---|
Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=38205117&ln= |
Concentration(Compounding value) | 9-11(mmol/L) |
---|---|
Appearance(A408935) | Colorless Transparent Liquid |
Record the entire process by video | Conform |